Description
Book SynopsisThe emergence of nanotherapeutics is attributable to the integration of nanotechnology, recombinant DNA technology, and synthetic organic chemistry with medicine for treating critical human diseases in a more efficient and specific molecular approach than therapy with conventionally-designed and formulated drugs. Nanotherapeutics: From Laboratory to Clinic comprehensively discusses the current shortcomings for delivery of classical (small) drugs, macromolecular therapeutics, and recombinant vaccine via the common intravascular and extravascular routes.
The book describes the synthetic/chemical engineering methods as well as recombinant, hybridoma, and phage display technologies to fabricate different types of nanoparticulate carriers and drugs. It also reveals the diversified approaches undertaken by harnessing nanotechnology to overcome the multistep extracellular and intracellular barriers and to facilitate the development of novel strategies for therapeutic de
Table of Contents
Emergence of nanotherapeutics: Challenges in classical drug transport versus macromolecular drug design. The ultimate destinations for delivery and release of nanotherapeutics. Diversity of bioactive nanoparticles from biological, chemical, and physical perspectives. Fabrication strategies for biofunctional nanoparticles. Interactions and orientation of therapeutic drugs in the vicinity of nanoparticles. Variable interactions of nanoparticles with blood, lymph, and extracellular and intracellular components. Pharmacokinetics and biodistribution of nanoparticles. Specific roles of nanoparticles in various steps of drug transport. Nanotechnology approaches to modulate transport, release, and bioavailability of classical and emerging therapeutics. Nanotechnology in the development of innovative treatment strategies. Nanoparticles for therapeutic delivery in animal models of different cancers. Nanoparticles for therapeutic delivery in animal models of other critical human diseases. Nanomedicine in clinical trials. Approved and commercialized nanomedicine. Current safety issues: Biodegradability, reactivity, and clearance. References.
